Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 13/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 11/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502749 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581752 | 0.93 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL29502730 | 0.93 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581753 | 0.91 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL29502728 | 0.91 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581773 | 0.91 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581772 | 0.91 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL29502753 | 0.88 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581778 | 0.88 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21581848 | 0.84 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20210032224-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| US-20210032224-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3575301-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-12-04 | — | — | EP | disclosed |
| EP-3575301-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312705-B2 | Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
| US-20210032224-A1 | HETEROARYL[4,3-C]PYRIMIDINE-5-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USES THEREOF | TBXA2R, ADORA1, ADORA2A | ADORA2A 3/4885ADORA2B 8/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.